Quest Diagnostics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on May 15, 2025. Quest Diagnostics Inc. (DGX) is a Delaware corporation headquartered in Secaucus, NJ.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following matters were voted upon at the Annual Meeting:
- Director Elections: All ten nominees were elected to terms expiring at the 2026 Annual Meeting. Notable "Against" votes included James E. Davis (7,692,258), Vicky B. Gregg (7,005,519), and Timothy M. Ring (7,378,294).
- Executive Compensation: The advisory resolution to approve executive officer compensation was approved with 85,922,577 votes "For" and 8,570,674 "Against".
- Independent Auditor: The ratification of PricewaterhouseCoopers as the independent registered public accounting firm for 2025 was approved with 95,585,333 votes "For" and 6,869,657 "Against".
- Stockholder Proposal: A proposal regarding calling a special meeting of stockholders was not approved, receiving 9,480,355 votes "For" and 84,410,956 "Against".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the specific reasons for the elevated "Against" votes for directors James E. Davis, Vicky B. Gregg, and Timothy M. Ring.
- Review the 2025 Proxy Statement for details on the executive compensation package that received approximately 9% opposition.
- Confirm the rationale behind the rejected stockholder proposal to call a special meeting.